16,100 Shares in Haemonetics Corporation $HAE Bought by Wesbanco Bank Inc.

Wesbanco Bank Inc. purchased a new position in shares of Haemonetics Corporation (NYSE:HAE) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 16,100 shares of the medical instruments supplier’s stock, valued at approximately $907,000.

Other large investors have also added to or reduced their stakes in the company. AQR Capital Management LLC lifted its holdings in shares of Haemonetics by 48.6% during the fourth quarter. AQR Capital Management LLC now owns 3,163,104 shares of the medical instruments supplier’s stock worth $253,523,000 after purchasing an additional 1,034,226 shares during the period. Arrowstreet Capital Limited Partnership increased its holdings in Haemonetics by 994.7% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier’s stock worth $110,615,000 after buying an additional 1,254,035 shares during the period. North Peak Capital Management LLC raised its position in Haemonetics by 204.4% during the 4th quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock worth $88,405,000 after buying an additional 740,626 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Haemonetics by 2.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,099,519 shares of the medical instruments supplier’s stock worth $53,587,000 after buying an additional 26,763 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in Haemonetics by 4,296.3% during the 3rd quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock valued at $37,685,000 after acquiring an additional 755,592 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Price Performance

Shares of NYSE HAE opened at $77.34 on Monday. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87. The stock has a market capitalization of $3.51 billion, a price-to-earnings ratio of 38.29, a PEG ratio of 1.56 and a beta of 0.55. The firm’s 50 day simple moving average is $65.41 and its 200-day simple moving average is $66.76. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $87.32.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.01. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The firm had revenue of $346.35 million during the quarter, compared to analysts’ expectations of $336.83 million. During the same period in the previous year, the business posted $1.24 EPS. The business’s revenue was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Analysts expect that Haemonetics Corporation will post 5.22 EPS for the current year.

Analysts Set New Price Targets

HAE has been the topic of several recent research reports. Robert W. Baird set a $67.00 price objective on shares of Haemonetics in a report on Friday, May 8th. Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Citigroup upped their price target on shares of Haemonetics from $64.00 to $70.00 and gave the company a “neutral” rating in a report on Thursday, May 28th. Bank of America raised Haemonetics from a “neutral” rating to a “buy” rating and increased their price target for the stock from $72.00 to $80.00 in a research report on Friday, May 22nd. Finally, Mizuho lifted their price objective on Haemonetics from $70.00 to $85.00 and gave the company an “outperform” rating in a research note on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $78.33.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.